University Hospital of Aarhus
Aarhus, 8000, Denmark
NCT Number: NCT01209416
This study will investigate the non-growth-hormone-dependent metabolic effects of the hormone Ghrelin in growth hormone deficient subjects by examining the insulin tolerance as well as signal proteins in fat and muscle biopsies.
Looking for future studies?
Notify Me18 year–65 year
Male
Interventional
Not applicable
Aarhus, 8000, Denmark
Ghrelin is a relatively 'new' hormone that is produced in the stomach and to a lesser extend in the hypothalamus of the brain. The actions of ghrelin are diverse and includes stimulation of the appetite center of the brain and the release of growth hormone. We have for the first time shown that ghrelin also stimulates the metabolism of fatty acids and induces insulin resistance in skeletal muscle. These effects have we confirmed in growth hormone deficient subjects on a stabile substitution treatment with growth hormone and hydrocortisone. With these subjects we can investigate the effects of ghrelin that are independent of growth hormone. The present study is a continuation of these findings, as we wish to investigate whether the insulin resistance effect of ghrelin is dependent of the concomitant metabolism of fatty acids. This is possible by administration of the niacin acid antagonist Acipimox, that blocks the fatty acid metabolism reversibly. We have applied this experimental principle in other settings with success.
Knowledge of the effects of ghrelin in general can in shot-sight as well as in long-sight have great importance for the understanding of growth disorders from overweight and type 2 diabetes to malnutrition and eating disorders.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
Other names: Tablet Olbetam 250 mg
Ghrelin infusion 4.2 ng/kg/min throughout the investigation day
placebo tablets or saline infusion
Other names: Placebo tablets, Saline infusion
Time frame: 5 hours investigation day
Growth hormone deficient patient investigated with ghrelin infusion and pharmacological antilipolysis (Acipimox) in a randomized cross-over study with 4 study days. During each visit signal proteins in muscle and fat biopsies are investigated with PCR, wester blot and activity assays for ghrelin, growth hormone and insulin. Further is glucose metabolism investigated in basal conditions and during hyperinsulinemic euglycemic clamp.
Time frame: 5 hours investigation day
Effects of ghrelin on heart rate variability
Time frame: 5 hours investigation day
Effects of ghrelin on thirst, fluid intake, urine production and natriuresis
University of Aarhus
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05307367
Adipose Tissue, Atrophy
Copenhagen, DK, Denmark
View Trial DetailsNCT05443347
Appetite, Body Weight
Kansas City, Missouri, United States
View Trial DetailsNCT01935323
Body Weight, Glucose Metabolism Disorders
Birmingham, Alabama, United States
View Trial DetailsNCT00476879
Behavior, Digestive System Diseases
Aarhus, Denmark
View Trial Details